Phuong Dang

  • 1575 Citations
  • 11 h-Index
If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Mrs Phuong Dang’s expertise is in the field of molecular biology and her role as Research Officer is to assist in a range of projects within the Leukamia Research Group. She has contributed to TKI drug transporter studies in CML and the screening of genetic alterations and mutations in ALL. Her current focus is on performing highly sensitive DNA QPCR in sorted cells from CML patients who are in Treatment Free Remission (TFR) or who have relapsed to investigate which population(s) of cells the leukaemia reside in.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2006 2019

  • 1575 Citations
  • 11 h-Index
  • 13 Article
  • 6 Letter

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Ross, D. M., Pagani, I., Irani, Y., Clarson, J., Gray, T., Dang, Y., McLean, J., Saunders, V., Carne, L., Reynolds, J., Ritchie, D. S., White, D., Branford, S., Hughes, T. & Yong, A., 1 Aug 2019, In : British Journal of Haematology. 186, 3, p. e56-e60

Research output: Contribution to journalLetter

5 Citations (Scopus)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., Braley, J., White, D. L., Yeung, D. T., Branford, S., Hughes, T. P. & Ross, D. M., 30 Nov 2018, In : Haematologica. 103, 12, p. 2026-2032 7 p.

Research output: Contribution to journalArticle

Open Access
1 Citation (Scopus)

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG), 1 Dec 2018, In : Leukemia. 32, 12, p. 2572-2579 8 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions

Sadras, T., Heatley, S. L., Kok, C. H., Dang, Y., Galbraith, K. M., McClure, B. J., Muskovic, W., Venn, N. C., Moore, S., Osborn, M., Revesz, T., Moore, A. S., Hughes, T. P., Yeung, D., Sutton, R. & White, D. L., 30 Aug 2017, In : Cancer Letters.

Research output: Contribution to journalArticle